We are scientists.
We are engineers.
We are drug hunters. We are insitro.

Dana Pe’er, Ph.D.

Dana Pe’er, Ph.D., is Chair of the Computational and Systems Biology Program, Alan and Sandra Gerry endowed chair and Scientific Director of the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at the Sloan Kettering Institute and has been selected as an HHMI investigator.

Dr. Pe’er’s lab develops novel computational techniques to characterize gene regulation at the single-cell level, in the context of complex tissues such as the tumor microenvironment. Recent work has focused upon the characterization of cell types, their organization along developmental trajectories, and the delineation of regulatory circuits that control cellular identity and behavior. Research questions include how diverse cell types evolve or act in a coordinated fashion within a tissue, particularly in the context of tumor immune ecosystems. The Pe’er lab is also developing analytical tools for new imaging-based technologies that combine high-resolution molecular profiling with spatial information.

Dr. Pe’er received her Bachelor’s degree in mathematics, and her PhD in computer science with Dr. Nir Friedman, at the Hebrew University of Jerusalem. At Harvard University, she trained as a postdoctoral research fellow in the department of genetics in the lab of Dr. George Church. Dr. Pe’er has received numerous honors, including a Burroughs Wellcome Fund Career Award, an NSF CAREER award, an NIH Director’s New Innovator Award, an NIH Director’s Pioneer Award, the Packard Fellowship in Science and Engineering, the ISCB Overton Prize and MD Anderson’s Ernst W. Bertner Memorial Award . She currently serves on the editorial board of the journal Cell, leads a Center within the NCI Human Tumor Atlas Network, and sits on the organizing committee of the Human Cell Atlas project, heading the computational analysis for this project.

Daniel MacArthur, Ph.D.

Daniel MacArthur, Ph.D. is the Director of the Center for Population Genomics, established to solve the critical scientific, regulatory, and technical problems currently limiting the development of genomic medicine in Australia, and execute large-scale projects that will establish Australia’s leadership in this field.

He previously served as Co-Director of the Medical and Population Genetics Program at the Broad Institute of MIT and Harvard, and headed up a team jointly based at the Broad Institute, Massachusetts General Hospital, and Harvard Medical School. He co-directed the Broad Institute’s Center for Mendelian Genomics, which has sequenced and analyzed genomic data from over 10,000 individuals from rare disease families and contributed to the discovery of more than 100 new rare disease genes.

He also led the development of the Genome Aggregation Database (gnomAD), the largest and most widely-used data set of human exome and genome sequence data, which has collated data from over 140,000 sequenced individuals.

David R. Liu, Ph.D.

Gene Yeo, Ph.D., MBA

George Davey Smith, MD, DSc, FRS

Giovanna Mallucci, MD, PhD

Oliver Stegle, Ph.D.

Roger Perlmutter, M.D., Ph.D., Independent Board Director

Roger Perlmutter, M.D., Ph.D., is President, Chief Executive Officer, and Chairman of Eikon Therapeutics, Inc., a private biotechnology company that employs advanced imaging technologies to identify novel therapeutic candidates by virtue of their effects on protein dynamics in living cells. A highly accomplished industry as well as academic leader with over 35 years of experience, Dr. Perlmutter was previously Executive Vice President, Merck & Co., and President of Merck Research Laboratories where he supervised the discovery and development of numerous lifesaving medicines including KEYTRUDA™ , Merck’s foundational immuno-oncology therapeutic, which continues to transform cancer care throughout the world. Before this, Dr. Perlmutter spent 12 years as Executive Vice President and head of R&D at Amgen, Inc., where he is credited with having revolutionized the development of important biopharmaceuticals for the treatment of osteoporosis and cancer-related bone disease, and for the reduction of hypercholesterolemia-related cardiovascular risk.

Prior to assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, Seattle, and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to his role at the University of Washington, he was a lecturer in the Division of Biology at the California Institute of Technology, Pasadena.

Dr. Perlmutter is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science, and both a Distinguished Fellow and past president of the American Association of Immunologists.

Scott L. Friedman, M.D.

Sir John Bell GBE, FRS

Tommi S. Jaakkola, Ph.D.